Dea Siggaard Stenbæk
Biographic Data
| ID | 7180923 |
|---|---|
| NAME | Dea Siggaard Stenbæk |
| GIVEN NAMES | Dea Siggaard |
| FAMILY NAME | Stenbæk |
| SIGNATURE | STENBÆK D S |
| AFFILIATIONS | Rigshospitalet |
| ORCID | 0000-0002-5439-4637 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression
Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention
Research suggests positive changes in both well-being and psychiatric symptoms following a psychedelic experience. One explanation may be the ability of psychedelic compounds to occasion mystical-type experiences. The Revised Mystical Experiences Questionnaire (MEQ30) is designed to assess the intensity and quality of such experiences. We examined the validity, reliability, and factor structure of a Danish translation of the MEQ30 in one sample o…
Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers
The study was registered at clinicaltrials.gov prior to initiation (NCT02869035; 08.16.2016, URL: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02869035&cntry=&state=&city=&dist=)
No prominent works on this page.
Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers
The study was registered at clinicaltrials.gov prior to initiation (NCT02869035; 08.16.2016, URL: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02869035&cntry=&state=&city=&dist=)
Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention
Research suggests positive changes in both well-being and psychiatric symptoms following a psychedelic experience. One explanation may be the ability of psychedelic compounds to occasion mystical-type experiences. The Revised Mystical Experiences Questionnaire (MEQ30) is designed to assess the intensity and quality of such experiences. We examined the validity, reliability, and factor structure of a Danish translation of the MEQ30 in one sample o…
Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression
Psilocybin (2 works) · Psychedelics and Drug Studies (2 works) · Psychiatry (2 works) · Psychology (2 works) · Chemical synthesis and alkaloids (1 works) · Clinical Psychology (1 works) · Clinical Psychology (1 works) · Cognition (1 works) · Confirmatory factor analysis (1 works) · Danish (1 works)